OliPass

Focus: OliPass is a Korean biotechnology company focused on peptide nucleic acid (PNA) derivatives for therapeutic applications. The company is early-stage with a nascent pipeline in pain and osteoarthritis indications.

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

About OliPass

AI assessmentNot Hiring

No open roles listed right now. Follow OliPass to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

OLP-1002

Pain

Phase 1

Clinical Trials (1)

NCT03760913OLP-1002 is Being Studied in the Treatment of Pain.

Phase 1

Help build intelligence for OliPass

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to build from the ground up in an emerging therapeutic modality (PNA derivatives) with limited competition
Early-stage pipeline with multiple clinical programs provides exposure to drug development across Phase 1-2
Korea-based biotech offers alternative career path in growing Asia-Pacific biotech ecosystem

Watch Out For

No revenue, no disclosed funding, or employee count indicates pre-commercial stage with uncertain runway and cash stability
Limited pipeline depth (3 trials total, no Phase 3 programs) and zero publications suggest early proof-of-concept stage with execution risk
No active job postings and sparse public visibility create questions about growth trajectory and organizational capacity

Generated by Claude from OliPass's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

A: OLP-1002

Osteoarthritis

Phase 1

Clinical Trials (1)

NCT04677933A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Multiple Subcutaneous Doses of OLP-1002

Phase 1

OLP-1002

Osteoarthritis

Phase 2

Clinical Trials (1)

NCT05216341Study of OLP-1002 Injections for Reducing Moderate to Severe Pain Due to Osteoarthritis in Hip and/or Knee Joint

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 3 clinical trials

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo